Evidence map›Paper›PMID 24699885›Full record

ReviewJournal of clinical immunology2014

Treatment of multifocal motor neuropathy with intravenous immunoglobulin.

Carol Lee Koski

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of clinical immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. MULTIFOCAL MOTOR NEUROPATHY: CASE REPORTS.Acta clinica Croatica · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Carol Lee KoskiGBS/CIDP Foundation International, 104 ½ Forrest Avenue, Narberth, PA, 19072, USA, clkoski@comcast.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multifocal motor neuropathy (MMN) is a rare inflammatory, chronically progressive, unremitting disorder affecting the peripheral nervous system. Although the etiology of this condition is not known, high titers of IgM Ab to GM1 may serve as a biomarker for this disease. Clinical findings of motor weakness are associated with focal conduction blocks and with time, axonal destruction. Evidence supporting an immune etiology as well as the use of intravenous immunoglobulin to limit the disease progression is reviewed.

Indexed as

AnimalsBiomarkersG(M1) GangliosideHumansImmunoglobulin MImmunoglobulins, IntravenousImmunotherapyMotor NeuronsNeural ConductionNeuroprotective AgentsPolyneuropathiesBiomarkersG(M1) GangliosideImmunoglobulin MImmunoglobulins, IntravenousNeuroprotective Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.